Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD

Image: Bristol-Myers Squibb has secured FDA breakthrough therapy status for Orencia to prevent moderate to severe acute graft-versus-host disease. Photo: courtesy of Rept0n1x.